2021-05-11T08:01:59-05:00 2020-12-31 050409384 KAHN LITWIN RENZA & CO LTD 951 NORTH MAIN STREET PROVIDENCE RI 02904 990 2020-01-01 522396428 ALZHEIMER'S DISEASE RESEARCH FOUNDATION D/B/A CURE ALZHEIMER'S FUND ALZH 7812373800 34 WASHINGTON ST NO 310 WELLESLEY HILLS MA 02481 TIMOTHY W ARMOUR PRESIDENT 7812373800 2021-05-10 1 TIMOTHY ARMOUR 999009999 SANDY ROSS P01399337 4012742001 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z CURE ALZHEIMER'S FUND TIMOTHY W ARMOUR 34 WASHINGTON ST NO 310 WELLESLEY HILLS MA 02481 22960715 0 X WWW. CUREALZ.ORG X 2004 PA TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE THROUGH VENTURE BASED PHILANTHROPY WITH ALL ORGANIZATIONAL EXPENSES PAID BY THE BOARD, ALLOWING ALL PUBLIC CONTRIBUTIONS TO DIRECTLY FUND ALZHEIMER'S RESEARCH. 7 6 22 35 0 0 30497342 22874388 0 0 85391 24835 0 0 30582733 22899223 16351728 14050077 0 0 2117985 2410583 0 0 1007026 5838314 4545719 24308027 21006379 6274706 1892844 13454870 16427042 552268 1631589 12902602 14795453 TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE THROUGH VENTURE BASED PHILANTHROPY WITH ALL ORGANIZATIONAL EXPENSES PAID BY THE BOARD, ALLOWING ALL PUBLIC CONTRIBUTIONS TO DIRECTLY FUND ALZHEIMER'S RESEARCH. 0 0 16691462 14050077 IN 2020 CURE ALZHEIMER'S FUND SUPPORTED 74 RESEARCH PROJECTS AT 59 LEADING RESEARCH INSTITUTIONS FOR A FUNDING TOTAL OF MORE THAN $16,000,000. PROJECTS PURSUED A DEEPER UNDERSTANDING OF THE MECHANISMS OF ACTION OF THE GENES AND VARIANTS WITH THE BIGGEST IMPACT ON RISK AND TIMING OF ALZHEIMER'S. OTHER PROJECTS PURSUED NOVEL THEORIES AND TOOLS TO TARGET AVENUES FOR PREVENTION AND TREATMENT. CUREALZ FUNDED DEVELOPMENT AND BREEDING OF TRANSGENIC ANIMAL MODELS; DIRECT SUPPORT OF FACILITATING GRANTS; AND HOSTED SCIENTIFIC MEETINGS. IN 2020, 133 PAPERS WERE PUBLISHED IN PREMIER SCIENCE JOURNALS, REFERENCING CUREALZ AS HAVING PROVIDED A GRANT FOR THE STUDY, BRINGING TOTAL PAPERS TO 740. CITATIONS OF THOSE PAPERS TOTALED 12,455 IN 2020, BRINGING TOTAL CITATIONS TO 47,292. 2194400 OTHER PROGRAM EXPENSES EXPANDED AWARENESS OF THE NEED TO FUND MORE RESEARCH INTO THE ORIGINS AND PROGRESSION OF ALZHEIMER'S DISEASE, AND COMMUNICATED SCIENTIFIC RESEARCH RESULTS TO THE PUBLIC. 18885862 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 27 0 22 1 0 0 0 0 0 0 0 0 0 0 0 0 X 7 6 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA X X X TIMOTHY W ARMOUR 7812383800 34 WASHINGTON STREET STE 310 WELLESLEY HILLS MA 02481 JEFFREY MORBY CO-CHAIRMAN 20.00 X X 0 0 0 HENRY MCCANCE CO-CHAIRMAN 5.00 X X 0 0 0 PHYLLIS RAPPAPORT TREASURER 2.00 X X 0 0 0 ROBERT GREENHILL DIRECTOR 2.00 X 0 0 0 JACQUELINE MORBY DIRECTOR 5.00 X 0 0 0 SHERRY SHARP DIRECTOR 2.00 X 0 0 0 BILL BENTER DIRECTOR (TO 3/20) 2.00 X 0 0 0 JAY JESTER DIRECTOR (TO 6/20) 5.00 X 0 0 0 TIMOTHY ARMOUR PRESIDENT & CEO 40.00 X X 270458 0 9336 MARGARET SMITH SECRETARY & SR VP 20.00 X 135578 0 14009 LAUREL LYLE VICE PRESIDENT 40.00 X X 74056 0 2229 BARBARA CHAMBERS SENIOR VICE PRESIDENT 40.00 X 182395 0 19139 JOHN SLATTERY SENIOR VICE PRESIDENT 40.00 X 183858 0 6082 KATHARINE HERMAN EXECUTIVE VICE PRESIDENT 40.00 X 347003 0 28635 1193348 0 79430 5 0 1 0 GRYPHON CONSULTING INC 21 DEAN ST BELMONT MA 02478 FINANCIAL & MGT CONSULTANT 217523 PROPER VILLIANS INC 668 STONY HILL RD YARDLEY MA 19067 CREATIVE AND PRODUCTION SERVICES 193785 PEARL STREET COLLECTIVE LLC 145 CHADWICK STREET NORTH ANDOVER MA 01845 RECRUITING EXPENSES 124666 3 22874388 6031416 22874388 15472 15472 70855 61492 9363 9363 9363 22899223 0 0 24835 11891254 11891254 2158823 2158823 898450 525599 215418 157433 1230516 761544 149709 319263 34744 19572 5223 9949 102470 52223 20350 29897 144403 91325 23324 29754 50097 29816 18991 1290 201259 201259 79066 79066 81 81 738235 313011 243796 181428 260053 259903 150 175279 47801 53984 73494 108780 7342 101438 183995 104823 34791 44381 34115 10551 5524 18040 200195 195921 4274 11213 11213 18800 2254 16546 RESEARCH LAB EXPENSES 2317941 2317941 GIFT PROCESSING FEES 126676 89 126587 MISCELLANEOUS 39934 17093 11755 11086 21006379 18885862 1113491 1007026 4437174 6191794 1293996 207998 6309700 3593695 65952 55727 54458 39076 26595 15382 1321453 6362446 13454870 16427042 143095 959088 500000 409173 172501 552268 1631589 X 6344297 10674191 6558305 4121262 12902602 14795453 13454870 16427042 1892844 7 0 X 0 1 X 1 0 X 16220862 17501551 19798072 30497342 22873948 106891775 16220862 17501551 19798072 30497342 22873948 106891775 12875997 94015778 611 13021 77320 83306 15472 189730 90 3644 3734 107085239 0.87800 0.88680 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 1 79065 0 0 79065 0 PART II-B, LINE 1(G) A REGISTERED LOBBYIST CONTACTED VARIOUS CONGRESSIONAL LEGISLATORS FOR THE PURPOSE OF ENCOURAGING INCREASED FUNDING OF ALZHEIMER'S DISEASE RESEARCH BY THE FEDERAL GOVERNMENT. 54458 39076 15382 15382 ACCRUED PAYROLL AND RELATED 172501 172501 X 22899149 7 7 22899142 81 81 22899223 21006298 0 21006298 81 81 21006379 PART X, LINE 2: THE ORGANIZATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH ITS TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVEL. THE ORGANIZATION ANNUALY FILES IRS FORM 990- RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES, GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE ORGANIZATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGESS. 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 1736324 NORTH AMERICA 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 422499 0 0 0 0 0 0 2158823 0 2158823 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM UNDERSTANDING, AND MIMICKING, THE BIOLOGICAL EFFECTS OF THE PLCY2 P522R VARIANT THAT PROTECT AGAINST AD 172485 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 2020 MANDELKOW MANDELKOW SCHNEIDER (YEAR 2) ; REVERSAL OF TAU PATHOLOGY BY AN ADENOSINE A1 RECEPTOR ANTAGONIST (YEAR 2) 287500 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SFRP1 AS A THERAPEUTIC TARGET AND DIAGNOSTIC/PROGNOSTIC FACTOR INALZHEIMER'S DISEASE (YEAR 1) 172500 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM PERSONALIZED DISEASE PREDICTION FOR ALZHEIMER'S DISEASE USING PROTEOME PROFILING: THE EPIC4AD STUDY 237816 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM NOVEL ENTRY ROUTES FOR THERAPEUTIC BIOLOGICALS TO THE BRAIN 172500 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM CIRCUITS: IDENTIFYING NOVEL EPIGENETIC BIOMARKERS 177375 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM PERSONALIZED DISEASE PREDICTION FOR ALZHEIMER'S DISEASE USING PROTEOME PROFILING: THE EPIC4AD STUDY 222161 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM UNDERSTANDING MOLECULAR BIOMARKER CHANGES IN ALZHEIMER'S DISEASE USING GENETICALLY DEFINED MOUSE MODELS (YEAR 2) 172500 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM APOE CONSORTIUM: TOWARD DEVELOPING HIGH DENSITY LIPOPROTEIN ENRICHED IN APOLIPOPROTEIN E AS A POTENTIAL BIOMARKER AND THERAPEUTIC TARGETING VASCULAR CONTRIBUTIONS TO ALZHEIMER'S DISEASE (YEAR 3) 249999 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SEX MATTERS: UNDERSTANDING THE INFLUENCE OF SEX AND APOE GENOTYPE ON HIPPOCAMPAL PLASTICITY AND COGNITION 172500 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM ABETA MEDIATED INHIBITION OF GAMMA-SECRETASE ACTIVITY INDUCES AD-RELEVANT CELLULAR PHENOTYPES (YEAR 2) 2020 MOBLEY CHAVEZ GUTIERREZ (YEAR 2) 121487 CHECK 9 0 0 0 0 0 0 PART III ACCOUNTING METHOD: 1 AMYLYX 43 THORNDIKE ST CAMBRIDGE MA 02141 464600503 100000 UNDERSTANDING AND MIMICKING THE BIOLOGICAL EFFECTS OF THE PLCY2 P522R VARIANCE THAT PROTECT AGAINST AD ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 830621846 501 (C)(3) 100000 IMPROVING ALZHEIMERS DISEASE CLINICAL TRIALS DESIGN BY MACHINE LEARNING LABS BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501 (C)(3) 172500 CIRCUITS: INTERGRATING FUNCTIONAL MAPS TO DISCOVER MICRO RNA'S IN AD BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501 (C)(3) 250000 THE ROLE OF APOE IN MICROGLIA REGULATIONS IN NEURODEGENERATION (YEAR 3) BOSTON CHILDRENS HOSPITAL 300 LONGWOOD AVE BOSTON MA 02115 042774441 501 (C)(3) 300000 NEUROIMFLAMMATION CONSORTIUM: UNDERSTANDING THE CONSEQUENCES OF NON-CODING AD RISK ALLELES ON MICROGLIA FUNCTION DUKE UNIVERSITY SCHOOL OF MEDICINE 324 BLACKWELL ST WASHINGTON BLDG DURHAM NC 27701 562247203 501 (C)(3) 203281 SEX DIFFERENCES IN ALZHEIMER'S DISEASE PROGRESSION: FRAMINGHAM HEART STUDY HARVARD COLLEGE 677 HUNTINGTON AVE BOSTON MA 02115 042103580 501 (C)(3) 250000 NEUROINFLAMMATION CONSORTIUM: ASSESSING THE LINKS BETWEEN THE MS4A RISK GENES, MICROGLIA, AND ALZHEIMER'S DISEASE HARVARD COLLEGE 677 HUNTINGTON AVE BOSTON MA 02115 042103580 501 (C)(3) 172500 ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE HOUSTON METHODIST HOSPITAL FOUNDATION PO BOX 4384 HOUSTON TX 77210 760094743 501 (C)(3) 200000 3DDS CONSORTIUM: UNCOVERING THE MOLECULAR MECHANISMS OF SELECTED DRUG CANDIDATES DERIVED FROM SYSTEMATIC ALZHEIMER'S DRUG REPOSITIONING ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI BOX 1049 GUSTAVE L LEVY PLACE NEW YORK NY 10026 136171197 501 (C)(3) 172500 VGF-DERIVED PEPTIDE THERAPY FOR AD: STUDIES OF MOUSE AND HUMAN TLQP-21 AND ITS RECEPTOR, C3AR1 (YEAR 1) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 345000 NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE (YEAR 2) CHOI & WRANN MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 402500 3DDS CONSORTIUM: MODULATING CD33 FUNCTION AND NEUROINFLAMMATION AS A THERAPEUTIC APPROACH FOR ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 350000 MICROBES AND ALZHEIMER'S DISEASE: METAGENOMICS ON SALIVA, CSF, BLOOD AND BRAIN MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 450000 CHARACTERIZING GUT MICROBIOME SYNERGY WITH EMPHASIS ON MYCOBIOME AND ITS IMPACT ON ALZHEIMER'S DISEASE (AD) PATHOLOGY IN AD MOUSE MODEL MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172500 GENES TO THERAPIES (G2T) CENTRALIZED RESEARCH MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 1725000 THE CUREALZ ALZHEIMER'S GENOME PROJECT MAYO CLINIC 200 FIRST ST SW ROCHESTER MN 55905 416011702 501 (C)(3) 172500 SENESCENT CELLS AND ALZHEIMER'S DISEASE (YEAR 2) MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD S JACKSONVILLE FL 32224 593337028 501 (C)(3) 172500 ABCA7 LOSS OF FUNCTION IN AGING AND ALZHEIMER'S DISEASE (YEAR 1) MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD S JACKSONVILLE FL 32224 593337028 501 (C)(3) 250000 APOE CONSORTIUM: COUNTERACTING PATHOGENIC EVENTS IN AD WITH PERIPHERAL OR CENTRAL APOE (YEAR 3) MGH NEUROLOGY REASEARCH 15 PARKMAN ST 835 BOSTON MA 02114 041564655 501 (C)(3) 250000 CREATION OF FIBROBLAST/IPS CELL BANK TO FACILITATE PERIPHERAL/BRAIN COMPARISONS, AND ALLOW MOLECULAR INVESTIGATIONS INTO MOLECULAR MECHANISMS UNDERLYING DIFFERENCES IN DISEASE AGGRESSIVENESS (YEAR 1) NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 1ST AVE R607 NEW YORK NY 10016 135562308 501 (C)(3) 250000 NEUROINFLAMMATION CONSORTIUM: INVESTIGATION OF AD RISK ALLELES IN ASTROCYTES FOCUS ON CHOLESTEROL TRANSPORT AND MICROGLIA INTERACTIONS (YEAR 2) STANFORD UNIVERSITY 450 SERRA MALL STANFORD CA 94305 941156365 501 (C)(3) 172500 A TRANSCRIPTIONAL REJUVENATION SIGNATURE FOR ALZHEIMER'S DISEASE THE BROAD INSTITUTE INC 415 MAIN ST CAMBRIDGE MA 02142 263428781 501 (C)(3) 550000 CIRCUITS: CONSORTIUM TO INFER REGULATORY CIRCUITS AND UNCOVER INNOVATIVE THERAPEUTIC STRATEGIES PRODUCTION GROUP THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501 (C)(3) 250000 APOE CONSORTIUM: REGULATION BY APOE OF SELECTIVE NEURONAL VULNERABILITY TO ALZHEIMER'S DISEASE (YEAR 3) THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 N TORREY PINES ROAD LA JOLLA CA 92037 952160097 501 (C)(3) 115000 CIRCUITS: IMPACT OF GENETIC, EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMER'S DISEASE PATHOLOGY THE TRUSTEES OF BOSTON UNIVERSITY 25 BUICK STREET BOSTON MA 02115 042103547 501 (C)(3) 172500 3DDS CONSORTIUM: PROTEOMICS OF ALZHEIMER'S DISEASE 3D CULTURES TRUSTEES OF TUFTS COLLEGE 150 HARRISON AVE BOSTON MA 02111 042103634 501 (C)(3) 172500 IN VIVO CHARACTERIZATION OF A LOSS OF FUNCTION GGA3 RARE VARIANT ASSOCIATED WITH AD (YEAR 1) THE UNIVERSITY OF CALIFORNIA IRVINE 535 ALDRICH HALL IRVINE CA 92697 952226406 501 (C)(3) 250000 NEUROINFLAMMATION CONSORTIUM: EXAMINING THE ROLE OF HUMAN MICROGLIA IN THE TRANSITION BETWEEN PARENCHYMAL AND VASCULAR BETAAMYLOID PATHOLOGY THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN RIVE LA JOLLA CA 92093 952872494 501 (C)(3) 143750 PHARMACOLOGICALLY PROTECTING AND RESCUING SYNAPSES FROM BETA AMYLOID BY RAISING SYNAPTIC PSD-95 (YEAR 2) THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN RIVE LA JOLLA CA 92093 952872494 501 (C)(3) 98921 ABETA MEDIATED INHIBITION OF GAMMA-SECRETASE ACTIVITY INDUCES AD-RELEVANT CELLULAR PHENOTYPES(YEAR 2) THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN RIVE LA JOLLA CA 92093 952872494 501 (C)(3) 259366 COMPREHENSIVE ANALYSES OF CHRONIC EFFICACY STUDIES WITH GSM 776890 FOR SUBMISSION OF THE PRE-IND BROCHURE TO THE FDA PRIOR TO PRE-IND MEETING AND IND FILING FOR THE SAD/MAD PHASE I SAFETY/TOXICITY AND ULTIMATELY FOR PHASE II AND PHASE III EFFICACY CLINICAL TRIALS TO SUPPORT THE NDA THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN RIVE LA JOLLA CA 92093 952872494 501 (C)(3) 172500 THE NEDD4-1 AND PKCA CONNECTION IN ALZHEIMER'S DISEASE (YEAR 1) THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN RIVE LA JOLLA CA 92093 952872494 501 (C)(3) 250000 NEUROINFLAMMATION CONSORTIUM: USING EPIGENETICS TO CHARACTERIZE THE REGULATION OF CELLULAR STATES IN MICROGLIA THAT CONTRIBUTE TO ALZHEIMER'S DISEASE PATHOLOGY UNIVERSITY OF CHICAGO 5235 S HARPER COURTH 4TH FLOOR CHICAGO IL 60615 362177139 501 (C)(3) 168434 EFFECT OF GUT MICROBIOME DYSBIOSIS ON NEUROINFLAMMATION AND A-DEPOSITION: A LONGITUDINAL MICRO-PET STUDY IN ALZHEIMER'S TRANSGENIC MICE UNIVERSITY OF NORTH CAROLINA CHAPEL HILL 130 MASON FARM ROAD CHAPEL HILL NC 27599 566001393 501 (C)(3) 172500 SMALL MOLECULE ACTIVATORS OF PLC-Y2 AS NOVEL UNIVERSITY OF SOUTHERN CALIFORNIA UNIVERSITY PARK LOS ANGELES CA 90089 951642394 501 (C)(3) 250000 MOLECULAR SIGNATURES OF APOE-MEDIATED BLOOD-BRAIN BARRIER DYSFUNCTION CAUSING NEURONAL AND SYNAPTIC DYSFUNCTION UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 752556007 501 (C)(3) 250000 MECHANISMS OF TAU PROPAGATION ACROSS THE PLASMA MEMBRANE UNIVERSITY OF VIRGINIA 1001 EMMET ST N CHARLOTTESVILLE VA 22903 546001796 501 (C)(3) 229249 ADULT HUMAN INERONS: A NEXT GENERATION DRUG SCREENING PLATFORM FOR ALZHEIMER'S DISEASE WAKE FOREST UNIVERSITY HEALTH SERVICES 1834 WAKE FOREST ROAD WINSTONSALEM NC 27109 223849199 501 (C)(3) 172500 INVESTIGATING THE ROLE OF TAU PROTEIN IN NEURONAL SENESCENCE INDUCTIONAND MAINTENANCE (YEAR 1) WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 21984 CHARACTERIZATION OF ALZHEIMER'S DISEASE MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOLOGICAL CONTINUUM (YEAR 1) WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 300000 APOE CONSORTIUM: UNDERSTANDING THE EFFECT OF APOE ON TAU-MEDIATED NEURODEGENERATION (YEAR 3) WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 247922 APOE CONSORTIUM: ASSESSING THE ADDED DIAGNOSTIC VALUE OF PERIPHERAL APOE PROTEIN LEVELS IN CURRENT BLOOD-BASED BIOMARKER ASSAYS FOR CNS AMYLOIDOSIS (YEAR 3) WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 172500 INVESTIGATING THE CONTRIBUTION OF ASTROCYTIC-DEPENDENT INFLAMMATION ON AMYLOID INDUCED TAU PATHOLOGY WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1167 YORK AVE NEW YORK NY 10065 136094042 501 (C)(3) 172500 VHTS FOR CD33 INHIBITORS WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1167 YORK AVE NEW YORK NY 10065 136094042 501 (C)(3) 172500 GUT MICROBIOTA, ENDOTHELIAL DYSFUNCTION AND TAU-MEDIATED COGNITIVE IMPAIRMENT WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 9 CAMBRIDGE CENTER CAMBRIDGE MA 02142 061043412 501 (C)(3) 172500 CIRCUITS: IMPACT OF GENETIC, EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMER'S DISEASE PATHOLOGY YALE UNIVERSITY 333 CEDAR ST NEW HAVEN CT 06510 060646973 501 (C)(3) 172500 ROLE OF MICROGLIAL PROTEIN SPARC IN CONTROL OF INFLAMMASOME ACTIVATION (YEAR 2 OF 2) 32 PART I, LINE 2: THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROPOSAL FOR FIT WITH THE CURE ALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A THREE-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT PROPOSAL FITS WITHIN THE ORGANIZATION'S MISSION TO FUND RESEARCH CONTRIBUTING TO A CURE FOR ALZHEIMER'S DISEASE. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. X X X X 0 0 0 0 0 0 0 0 0 TIMOTHY ARMOUR PRESIDENT & CEO 270458 0 0 0 0 0 9336 0 0 0 279794 0 0 0 BARBARA CHAMBERS SENIOR VICE PRESIDENT 182395 0 0 0 0 0 6635 0 12504 0 201534 0 0 0 JOHN SLATTERY SENIOR VICE PRESIDENT 183858 0 0 0 0 0 6082 0 0 0 189940 0 0 0 KATHARINE HERMAN EXECUTIVE VICE PRESIDENT 347003 0 0 0 0 0 10908 0 17727 0 375638 0 0 0 PROPER VILLIANS INC A PRINCIPAL OF THE VENDOR IS THE SPOUSE OF A KEY EMPLOYEE 193785 CREATIVE AND PRODUCTION SERVICES 0 X 80 6030976 SALE PRICE 0 0 0 1 PART I, LINE 32B: WHEN STOCK IS RECEIVED AS A CONTRIBUTION IT IS SOLD IMMEDIATELY UPON RECEIPT OR SOON THEREAFTER AS IS PRACTICAL THROUGH BANK OF NEW YORK/MELLON. FORM 990, PART VI, SECTION A, LINE 2 JEFFREY MORBY AND JACQUELINE MORBY ARE BOTH DIRECTORS AND SPOUSES. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY THE PRESIDENT AND CONTRACT CFO. REVISIONS, CORRECTIONS, ETC. ARE MADE AS NECESSARY. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL BOARD MEMBERS. FORM 990, PART VI, SECTION B, LINE 12C EACH YEAR THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS PROVIDED TO ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES. THESE PEOPLE ARE ASKED TO REVIEW THE POLICY AND SIGN A STATEMENT INDICATING THAT THEY UNDERSTAND THE POLICY AND HAVE REPORTED ALL POTENTIAL CONFLICTS DURING THE PAST YEAR IN ACCORDANCE WITH THE POLICY AND WILL REPORT ALL POTENTIAL CONFLICTS DURING THE COMING YEAR. ALL POTENTIAL CONFLICTS ARE EVALUATED BY THE BOARD TO DETERMINE IF A CONFLICT ACTUALLY EXISTS. IN THOSE INSTANCES WHERE THE POTENTIAL TRANSACTION IS A CONFLICT, THE BOARD EXAMINES THE TRANSACTION AND A VOTE IS TAKEN (WITH THOSE INVOLVED RECUSING THEMSELVES) AS TO WHETHER THE ORGANIZATION WILL ENTER INTO THE TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 COMPARABILITY DATA IS SUBMITTED ANNUALLY TO THE EXECUTIVE COMMITTEE FOR COMPENSATION APPROVAL FOR THE PRESIDENT AND ALL OTHER EMPLOYERS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST AND AT THE ORGANIZATION'S WEBSITE.